AngioWaveNet vs Tempus ECG-Low EF
AI Verdict
Choose AngioWaveNet if…
Choose AngioWaveNet if your primary objective is to enhance the clarity and detail of fluoroscopic angiograms during interventional cardiac or vascular procedures. This AI software is ideal for improving real-time vessel visualization, aiding clinicians in navigating complex vascular structures and making more informed decisions within the cath lab workflow.
View AngioWaveNet →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if you need an AI-powered solution for early detection and risk stratification of low left ventricular ejection fraction (LVEF) using standard 12-lead ECGs. This tool is best suited for identifying patients 40 years or older at risk of heart failure, facilitating timely follow-up and further diagnostic evaluation.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AngioWaveNet | Tempus ECG-Low EF |
|---|---|---|
| Pricing | Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. | Unknown |
| Deployment | Cloud-based or on-premise/servers | Integrates with current ECG platforms and electronic health records (EHRs). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AngioWaveNetAngioWaveNet emphasizes vendor-agnostic compatibility with any fluoroscopic angiography system and seamless integration into existing Cath lab workflows, requiring minimal training and offering intuitive design. It processes angiographic cines automatically, allowing clinicians to review original and enhanced versions side-by-side without delaying procedures. Tempus ECG-Low EF, while integrated into workflows and providing a clear binary output, operates more as a backend system without a dedicated user interface for direct interaction.
Clinical Value
Tempus ECG-Low EFTempus ECG-Low EF provides significant clinical value by detecting signs of low left ventricular ejection fraction (LVEF u226440%) from routine ECGs, identifying patients at risk of heart failure with 85.8% sensitivity and 83.0% specificity. This offers a novel screening capability from an inexpensive test, enabling earlier identification and intervention for a widespread condition. While AngioWaveNet enhances vessel visualization during procedures, improving existing diagnostic quality, Tempus ECG-Low EF extracts new, actionable diagnostic information from standard data.
Pricing & Value
AngioWaveNetAngioWaveNet offers transparent and flexible pricing options, including annual software licensing or subscription-based access tailored to cath lab volume and hospital needs, with custom packages available. In contrast, Tempus ECG-Low EF's pricing information is listed as 'contact vendor,' which lacks transparency. This makes AngioWaveNet a more straightforward option for budget planning and value assessment.
Enterprise Readiness
AngioWaveNetBoth tools are FDA-cleared and HIPAA compliant, indicating foundational enterprise readiness. However, AngioWaveNet explicitly offers both cloud-based and on-premise deployment options, along with vendor-agnostic compatibility for any fluoroscopic angiography system and DICOM endpoint functionality. This provides greater flexibility and adaptability for diverse enterprise IT infrastructures compared to Tempus ECG-Low EF's less detailed deployment specifics.
Innovation
Tempus ECG-Low EFTempus ECG-Low EF demonstrates higher innovation by leveraging AI to extract previously unavailable diagnostic information (risk of low LVEF) from standard 12-lead ECGs, effectively expanding the utility of a common, inexpensive test for early risk stratification. AngioWaveNet, while innovative in its AI-powered spatiotemporal enhancement, primarily improves the visualization of existing angiographic images. Tempus's approach creates a new diagnostic pathway for a critical condition.
Support & Docs
AngioWaveNetAngioWaveNet explicitly states it provides 'full onboarding support, including installation assistance, staff training, and access to ongoing updates and clinical resources.' This indicates a clear commitment to customer support and comprehensive documentation. The available information for Tempus ECG-Low EF does not detail comparable customer-facing support and documentation offerings.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AngioWaveNet | Tempus ECG-Low EF |
|---|---|---|
| Name | AngioWaveNet | Tempus ECG-Low EF |
| Company | Angiowave Imaging | Tempus AI |
| Description | FDA-cleared AI software that enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories, integrating with existing Cath lab workflows. | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. |
| Primary Function | Improved vessel visualization in fluoroscopic angiograms | Detects signs of low Left Ventricular Ejection Fraction (LVEF u226440%) |
| Key Technology | AI-powered Spatiotemporal Enhancement Processing (STEPu2122) | AI-powered algorithm for ECG analysis |
| Target Patient Population/Data | Fluoroscopic angiograms | 12-lead ECG recordings from patients 40 years or older at risk of heart failure |
Videos
Demos, reviews, and walkthroughs featuring AngioWaveNet and Tempus ECG-Low EF.
Frequently Asked Questions
More Comparisons
More matchups featuring AngioWaveNet or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.